Aspire Parramatta

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

Retrieved on: 
Wednesday, July 1, 2020
Aspire Parramatta, Parramatta, Akari, ADSS, Spacecraft, Shōnen manga, Spaceflight, Astronomy

Akari will control the timing and amount of all sales of its ADSs to Aspire Capital.

Key Points: 
  • Akari will control the timing and amount of all sales of its ADSs to Aspire Capital.
  • Akari is very pleased to announce a second facility with Aspire Capital, a long-term and supportive shareholder.
  • During the second quarter 2020, Akari raised an additional $9.3 million from Aspire thereby completing our initial $20 million agreement.
  • Were delighted to extend this additional commitment to Akari during such an important and exciting transition period for the company.

SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement

Retrieved on: 
Monday, April 13, 2020
Aspire Parramatta, Parramatta, Stock

SCYNEXIS will control the timing and amount of sales of common stock to Aspire Capital, if any.

Key Points: 
  • SCYNEXIS will control the timing and amount of sales of common stock to Aspire Capital, if any.
  • In addition, the Purchase Agreement may be terminated by SCYNEXIS at any time, at its discretion, without any cost to SCYNEXIS.
  • As consideration for Aspire Capitals obligation under the Purchase Agreement, SCYNEXIS issued 709,103 shares to Aspire Capital as a commitment fee.
  • SCYNEXIS also entered into a registration rights agreement with Aspire Capital in connection with its entry into the Purchase Agreement.

Aspire Regenerative and Cortex Wellness Pharmacy Co-Host Weight Loss Event

Retrieved on: 
Wednesday, February 19, 2020
Regeneration, Aspire Parramatta

SAN DIEGO, Feb. 19, 2020 /PRNewswire-PRWeb/ --Aspire Regenerative, a leader in offering therapies that restore healthy tissues in the body to promote wellness, partners with Cortex Wellness Pharmacy for a free weight-loss event on March 1, 2020.

Key Points: 
  • SAN DIEGO, Feb. 19, 2020 /PRNewswire-PRWeb/ --Aspire Regenerative, a leader in offering therapies that restore healthy tissues in the body to promote wellness, partners with Cortex Wellness Pharmacy for a free weight-loss event on March 1, 2020.
  • One such device that will be featured at the event is the innovative InBody Scale, a service offered by Aspire Regenerative.
  • The March 1 event at Cortex Wellness Pharmacy is ideal for anyone ready to embark on a medically sound weight-loss regimen.
  • About Aspire Regenerative: Aspire Regenerative is a state-of-the-art medical practice offering personalized regenerative treatments and integrative therapies to help patients reach their goals and achieve the best possible results.

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

Retrieved on: 
Monday, October 28, 2019
Finance, Corporate finance, Equity securities, Money, Financial economics, Aspire Parramatta, Parramatta, Financial capital, Common stock, Stock

Under the agreement, Aspire Capital is committed to purchase up to $10.9 million of Salarius common stock over a 30-month span extending into 2022, subject to certain terms and conditions.

Key Points: 
  • Under the agreement, Aspire Capital is committed to purchase up to $10.9 million of Salarius common stock over a 30-month span extending into 2022, subject to certain terms and conditions.
  • This common stock purchase agreement with Aspire Capital provides Salarius with additional access to capital and financing flexibility allowing Salarius to further advance its lead drug candidate, Seclidemstat, commented David Arthur, Chief Executive Officer of Salarius.
  • Under the terms of the agreement with Aspire Capital, Salarius retains full control over the timing of any stock sales made under the agreement and the amount of stock sold to Aspire Capital.
  • In addition to the Common Stock Purchase Agreement, Salarius also entered into a Registration Rights Agreement with Aspire Capital.

Titan Medical Announces Common Share Purchase Agreement With Aspire Capital Fund of up to US$35 Million

Retrieved on: 
Thursday, August 29, 2019
Biotechnology, Health, Medical devices, Leyland Titan, Titan, Aspire Parramatta, Military of the United States, Science and technology in the United States

Titan Medical Inc. (Titan or the Company) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS), announces that it has entered into a Common Share Purchase Agreement (the Agreement) with Aspire Capital Fund, LLC (Aspire Capital) where Aspire Capital has committed to purchase up to US$35.0 million of common shares of Titan at Titans request from time to time, until February 28, 2022.

Key Points: 
  • Titan Medical Inc. (Titan or the Company) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS), announces that it has entered into a Common Share Purchase Agreement (the Agreement) with Aspire Capital Fund, LLC (Aspire Capital) where Aspire Capital has committed to purchase up to US$35.0 million of common shares of Titan at Titans request from time to time, until February 28, 2022.
  • On commencement of the Agreement, Titan will immediately sell to Aspire Capital 1,777,325 common shares at a price of US$1.6879 per share for gross proceeds of US$3.0 million.
  • On any business day, Titan shall have the right to direct Aspire Capital to purchase up to 100,000 common shares with a value not exceeding US$500,000.
  • Under the terms of the Agreement, Titan will immediately issue 639,837 common shares to Aspire Capital as a commitment fee (the Commitment Shares).